Overview
The objectives of this study are:
- To determine the prevalence and degree of hyperprolactinemia in children and adolescents aged 7-18 years receiving antipsychotic medications
- To determine the associations between serum-prolactin and sex hormones / metabolic biomarkers/ clinical symptoms in this population. If clinically relevant associations are found: To determine a potentially existing "no harm" serum-prolactin threshold
- To determine associations between previous cumulative prolactin-exposure and current pubertal development / growth
Eligibility
Inclusion Criteria:
- • In daily treatment with antipsychotic medication belonging to Anatomical Therapeutic Chemical (ATC) group N05A (except N05AN lithium) for a minimum duration of 3 months prior to inclusion
Exclusion Criteria:
- Eating Disorder
- Medical treatment to change sex
- Pregnancy or lactation